Clinical Trial Update: Continuing Sodium Zirconium Cyclosilicate (SZC) After Discharge Study [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating continuing sodium zirconium cyclosilicate after discharge in patients with hyperkalemia and chronic kidney disease has completed and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Hyperkalemia

Drugs mentioned

• Lokelma (sodium zirconium cyclosilicate)

Snippet

Sponsor: AstraZeneca | Conditions: Hyperkalaemia, Chronic Kidney Disease | Phase 4 | Status: COMPLETED | Results posted: 2025-11-28